Skip to main content
. Author manuscript; available in PMC: 2012 Jan 18.
Published in final edited form as: Neuroscience. 2011 Jun 13;190:339–345. doi: 10.1016/j.neuroscience.2011.06.004

Fig. 3.

Fig. 3

T1DM increases RAGE, TLR4 and MMP-9 expression in the ischemic brain. Niaspan treatment in T1DM-MCAo rats attenuates RAGE, TLR4 and MMP-9 expression in the ischemic brain. RAGE, TLR4 and MMP9 expression are colocalized with ED1 in the ischemic brain in T1DM rats. (A) RAGE immunostaining in the ischemic brain in WT-MCAo, T1DM-MCAo and T1DM-MCAo+Niaspan treatment animals (arrow identifies RAGE positive cell). (B) TLR4 immunostaining in the ischemic brain in WT-MCAo, T1DM-MCAo and T1DM-MCAo+Niaspan treatment animals (arrow identifies TLR4 positive cell). (C) MMP-9 immunostaining in the ischemic brain in WT-MCAo, T1DM-MCAo and T1DM-MCAo+Niasapn treatment animals (arrow identifies MMP9 positive cell). (D–F) Double immunostaining of TLR4 with ED1 (D, red: TLR4 positive cell; green: ED1 positive cell), RAGE with ED1 (E, red: RAGE positive cell; green: ED1 positive cell) and MMP9 with ED1 (F, red: MMP9 positive cell; green: ED1 positive cell) in the ischemic brain. n=8/group. * P<0.05 vs. WT-MCAo control. # P<0.05 vs. T1DM-MCAo control. Scale bar in (A–F)=50 µm.